![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Allos Therapeutics, Inc. (MM) | NASDAQ:ALTH | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.83 | 0 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 23, 2011 (June 21, 2011)
ALLOS THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware |
|
000-29815 |
|
54-1655029 |
(State or other jurisdiction |
|
(Commission |
|
(IRS Employer |
of incorporation) |
|
File Number) |
|
Identification No.) |
11080 CirclePoint Road, Suite 200 |
|
|
Westminster, Colorado |
|
80020 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrants telephone number, including area code: (303) 426-6262
Not applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Section 5 Corporate Governance and Management
Item 5.07 Submission of Matters to a Vote of Security Holders.
The 2011 Annual Meeting of Stockholders (the Annual Meeting ) for Allos Therapeutics, Inc. (the Company ) was held on June 21, 2011, for the following purposes:
· to elect seven nominees for the Board of Directors, each to serve until the 2012 Annual Meeting of Stockholders and until his successor has been elected and qualified or until his earlier death, resignation or removal;
· to approve, on an advisory basis, the compensation of the Companys named executive officers;
· to indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Companys named executive officers; and
· to ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2011.
At the meeting, each of Paul L. Berns, Stephen J. Hoffman, Ph.D., M.D., Jeffrey R. Latts, M.D., Jonathan S. Leff, Timothy P. Lynch, Nishan de Silva, M.D. and David M. Stout was re-elected as a director of the Company. The stockholders of the Company approved, on an advisory basis, the compensation of the Companys named executive officers. The stockholders of the Company indicated, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Companys named executive officers is every year. In addition, the stockholders of the Company ratified the appointment of Ernst & Young LLP as the Companys independent registered public accounting firm for the Companys fiscal year ending December 31, 2011. The final voting results on each of the matters submitted to a vote of stockholders at the Annual Meeting are as follows:
|
|
|
For |
|
Withheld |
|
Broker Non-Votes |
|
1. |
Election of Directors |
|
|
|
|
|
|
|
|
Paul L. Berns |
|
75,798,667 |
|
1,112,510 |
|
18,061,689 |
|
|
Stephen J. Hoffman, Ph.D., M.D. |
|
54,402,716 |
|
22,508,461 |
|
18,061,689 |
|
|
Jeffrey R. Latts, M.D. |
|
73,694,776 |
|
3,216,401 |
|
18,061,689 |
|
|
Jonathan S. Leff |
|
69,124,132 |
|
7,787,045 |
|
18,061,689 |
|
|
Timothy P. Lynch |
|
75,754,822 |
|
1,156,355 |
|
18,061,689 |
|
|
Nishan de Silva, M.D. |
|
75,861,792 |
|
1,049,385 |
|
18,061,689 |
|
|
David M. Stout |
|
70,110,171 |
|
6,801,006 |
|
18,061,689 |
|
|
|
For |
|
Against |
|
Abstentions |
|
Broker Non-Votes |
|
2. Approval, on an advisory basis, of the compensation of the Companys named executive officers |
|
40,411,714 |
|
36,437,226 |
|
62,237 |
|
18,061,689 |
|
|
|
1 year |
|
2 years |
|
3 years |
|
Abstentions |
|
Broker Non-Votes |
|
3. Indication, on an advisory basis, of the preferred frequency of stockholder advisory votes on the compensation of the Companys named executive officers |
|
38,351,290 |
|
2,303,246 |
|
36,197,885 |
|
58,756 |
|
18,061,689 |
|
|
|
For |
|
Against |
|
Abstentions |
|
|
|
4. Ratification of Ernst & Young LLP as independent registered public accounting firm for 2011 |
|
94,307,202 |
|
598,077 |
|
67,587 |
|
|
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: June 23, 2011
|
|
ALLOS THERAPEUTICS, INC. |
|
|
|
|
|
|
|
By: |
/s/ Marc H. Graboyes |
|
|
Marc H. Graboyes |
|
Its: |
Senior Vice President, General Counsel and Secretary |
1 Year Allos Therapeutics, Inc. (MM) Chart |
1 Month Allos Therapeutics, Inc. (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions